FermaWin 2.5 mg

FermaWin 2.5 mg is an oral tablet containing stanozolol, a Schedule III anabolic steroid. In medical practice, stanozolol is FDA-approved to decrease the frequency and severity of hereditary angioedema attacks. In non-medical bodybuilding contexts, it is referenced for cutting-phase physique enhancement, though such use falls outside approved indications.

The FDA-approved HAE dose is 2 mg three times daily, with gradual reduction to the minimal effective dose. Non-medical bodybuilding reference ranges cite 25–50 mg daily, split into two or three administrations. Stanozolol has an oral half-life of approximately 9 hours, supporting divided dosing.

Yes, in non-medical contexts, post-cycle therapy is commonly recommended because stanozolol suppresses endogenous testosterone production. Typical PCT protocols reference tamoxifen 40/40/20/20 mg or clomiphene 50/50/25/25 mg for 4 weeks, starting 24–48 hours after the last dose.

Stanozolol binds the androgen receptor, promoting nitrogen retention and protein synthesis. It also has fibrinolytic properties, stimulating plasminogen activator activity and reducing fibrinogen, which underlies its efficacy in hereditary angioedema. Unlike testosterone, stanozolol does not aromatize to estrogen or undergo 5-alpha reduction.

In HAE management, stanozolol's fibrinolytic effects normalize within approximately three months. In non-medical bodybuilding contexts, cosmetic effects (increased hardness and vascularity) are typically noticed around week three to four of a cycle.

No single oral steroid is universally superior. Stanozolol produces a drier, harder look compared to Anavar 10 (oxandrolone), but is significantly more hepatotoxic and damaging to lipid profiles. For most recreational users, oxandrolone is considered the safer oral option.

Both are DHT-derived oral steroids used for cutting, but Anavar 10 (oxandrolone) is milder on the liver and lipids while producing a slightly softer aesthetic. Stanozolol gives a drier, grainier look but is more hepatotoxic and more damaging to HDL cholesterol.

Dianabol 20 (methandienone) is a more potent mass-building oral that aromatizes to estrogen, causing water retention and gynecomastia risk. Stanozolol does not aromatize, making it suitable for cutting phases where a dry look is desired. Both are hepatotoxic 17α-alkylated steroids.

2.5 mg is the per-tablet strength of FermaWin. The FDA-approved HAE dose is 2 mg three times daily (6 mg total daily). Non-medical bodybuilding doses are substantially higher at 25–50 mg daily.

FermaWin 2.5 mg by Dragon Pharma contains 2.5 mg of stanozolol per tablet. It is supplied as 100 oral tablets per package. This is a research presentation.

In non-medical contexts, stanozolol is sometimes referenced alongside a testosterone base to mitigate suppression-related side effects. However, stacking with other 17α-alkylated orals (Dianabol, Anadrol, Superdrol) is contraindicated due to additive hepatotoxicity. Concurrent use of multiple oral steroids significantly increases the risk of serious liver injury.

Warning signs include yellowing of the skin or eyes (jaundice), dark urine, pale stools, right-upper-quadrant pain, nausea, and loss of appetite. These symptoms require immediate discontinuation and medical evaluation. Stanozolol is a documented cause of cholestatic liver injury.